Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
October 20 2015 - 10:00AM
Business Wire
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that additional clinical data on ARC-520, its RNAi
therapeutic candidate for the treatment of chronic hepatitis B
infection, will be presented in the late-breaking poster session at
The Liver Meeting® 2015, the 66th Annual Meeting of the American
Association for the Study of Liver Disease (AASLD) being held on
November 13-17, 2015, in San Francisco.
The late-breaking abstract details results from the Heparc-2001,
Phase 2 study of ARC-520 in combination with entecavir (ETV). Key
findings include the following:
- Naïve patients reduced viral DNA up
to 4.3 log (mean 2.2 log)
- Naïve e-antigen (HBeAg) positive
patients reduced surface antigen (HBsAg) up to 1.9 log (mean max
1.1 log)
- ARC-520 reduced HBeAg up to 1.7 log
(mean max 1.2 log)
- ARC-520 therapy was well tolerated
with no adverse events rated serious, severe, drug-related or
causing withdrawal from the trial
- 15 patients are continuing in
follow-up and additional results may be available to report at The
Liver Meeting
Christopher Anzalone, Ph.D., president and CEO of
Arrowhead, said, “In the Phase 2 study, ARC-520 effectively
inhibited cccDNA-derived mRNA with protein knockdown up to 99% or
1.9 logs observed. This is the highest knockdown ever reported
using RNAi in humans. Our clinical program and our study in
chronically infected chimps continue to teach us a lot about HBV
and we are thrilled to get the opportunity to make three
presentations at The Liver Meeting next month.”
With the addition of the late-breaking poster, Arrowhead has the
following three abstracts accepted for presentation at the Liver
Meeting:
November 15, 3:15 p.m. PST – Christine Wooddell, Ph.D., group
leader will deliver an oral presentation titled, “Reductions in
cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic
hepatitis B virus infection implicate integrated DNA in maintaining
circulating HBsAg”
November 16, 8:00 a.m. - 5:30 p.m. PST – Man-Fung Yuen, M.D.,
Ph.D., chair of gastroenterology and hepatology, The University of
Hong Kong, and deputy chief of service, Queen Mary Hospital
department of medicine, Hong Kong, will deliver a late-breaking
poster presentation titled, “ARC-520 produces deep and durable
knockdown of viral antigens and DNA in a phase II study in patients
with chronic hepatitis B”
November 17, 8:00 a.m. - 12:00 p.m. PST – Christine Wooddell,
Ph.D., group leader will deliver a poster presentation titled,
“Monthly dosing of ARC-520 in chronically hepatitis B virus
infected chimpanzees produces rapid, deep and durable reductions in
circulating viral antigens”
Additional details including presentation abstracts can be found
on the AASLD website by clicking this link. A copy of presentation
materials can be accessed by visiting the Events section of the
Arrowhead website after the presentations conclude.
About ARC-520
Arrowhead’s RNAi-based candidate ARC-520 is being investigated
in the treatment of chronic HBV infection. The small interfering
RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of
the reverse transcription process where current standard of care
nucleotide and nucleoside analogues act. Arrowhead is investigating
ARC-520 specifically to determine if it can be used to achieve a
functional cure, which is an immune clearant state characterized by
hepatitis B s-antigen negative serum with or without
sero-conversion. Arrowhead has completed a Phase 1 single ascending
dose study in normal volunteers and the company is conducting
single dose Phase 2a studies and multiple dose Phase 2b studies in
chronic HBV patients. Approximately 350-400 million people
worldwide are chronically infected with the hepatitis B virus,
which can lead to cirrhosis of the liver and is responsible for 80%
of primary liver cancers globally.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT
for liver disease associated with alpha-1 antitrypsin deficiency,
ARC-F12 for hereditary angioedema and thromboembolic diseases, and
ARC-HIF2 for renal cell carcinoma.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Arrowhead Research Corporation's most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss
some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no
obligation to update or revise forward-looking statements to
reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Research Corporation.
The Liver Meeting is a registered trademark of the
American Association for the Study of Liver Disease.
Source: Arrowhead Research Corporation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151020005585/en/
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupChad Rubin, 646-378-2947ir@arrowres.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024